文献速递心外重症与机械循环支持

胺碘酮与心脏移植后严重原发性移植物功能障碍的剂量依赖性关联

Dose-dependent association between amiodarone and severe primary graft dysfunction in orthotopic heart transplantation.
PubMed 文献 · J Heart Lung Transplant · 2017-05-20

该回顾性研究纳入269例成人原位心脏移植受者,其中100例移植前使用胺碘酮、169例未使用。结果显示胺碘酮使用是严重原发性移植物功能障碍(PGD)和院内死亡的独立危险因素,且严重PGD风险随胺碘酮剂量增加呈线性升高。

要点

  • 移植前使用胺碘酮者严重PGD发生率为20.0%,未使用者为5.3%(p<0.001)。
  • 胺碘酮使用是严重PGD的独立危险因素(OR 6.05,95%CI 2.47-14.83,p<0.001)。
  • 移植当日胺碘酮剂量每增加100 mg及6个月累积剂量每增加18,300 mg均与严重PGD风险升高相关。

核心结论

  • 移植前使用胺碘酮与严重PGD发生率及院内死亡率升高独立相关,且严重PGD风险随剂量增加呈线性升高。

研究设计与样本

  • 单中心回顾性研究,纳入2010至2014年间269例成人原位心脏移植受者,其中100例移植时使用胺碘酮(组1),169例未使用(组2)。

主要发现

  • 组1移植前肌酐高于组2(1.49 ± 0.63 vs 1.27 ± 0.68 mg/dl,p = 0.011)。
  • 等待名单时组1状态2比例高于组2(42.0% vs 29.0%),组2状态1A比例高于组1(20.7% vs 8.0%;p = 0.009)。
  • 严重PGD(移植后24小时内需机械循环支持)在组1显著更高(20.0% vs 5.3%,p < 0.001)。
  • 多变量分析中胺碘酮使用是严重PGD的独立危险因素(OR 6.05;95%CI 2.47-14.83;p < 0.001)及院内死亡的独立危险因素(OR 2.88;95%CI 1.05-7.88;p = 0.039)。
  • 移植当日胺碘酮剂量每增加100 mg(OR 1.55;95%CI 1.26-1.90)及6个月累积剂量每增加18,300 mg(OR 1.67;95%CI 1.31-2.15)与严重PGD风险升高相关(p均<0.001)。

临床怎么用

  • 对等待心脏移植患者使用胺碘酮时,应评估剂量累积与严重PGD风险,移植前优化抗心律失常策略可能有助于降低术后严重PGD风险。

局限性

  • 单中心回顾性设计,样本量有限,可能存在未测量混杂因素。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: There is growing concern regarding the association between pre-transplant amiodarone exposure and post-transplant adverse outcomes. We hypothesized that amiodarone use would be associated with the development of severe primary graft dysfunction (PGD) in a dose-dependent manner. METHODS: This was a retrospective review of 269 adult orthotopic heart transplantation (OHT) recipients at our institution between 2010 and 2014. At the time of OHT, 100 were receiving amiodarone therapy (Group 1) and 169 were not (Group 2). RESULTS: Pre-OHT creatinine was higher in Group 1 (1.49 ± 0.63 vs 1.27 ± 0.68 mg/dl, p = 0.011). At time of listing, Group 1 had higher frequency of status 2 (42.0% vs 29.0%), and Group 2 had higher frequency of status 1A (20.7% vs 8.0%; p = 0.009). Severe PGD (mechanical circulatory support within 24 hours post-OHT) was significantly higher in Group 1 (20.0% vs 5.3%, p < 0.001). Pre-OHT amiodarone use was an independent risk factor for severe PGD (odds ratio [OR], 6.05; 95% confidence interval [CI], 2.47-14.83; p < 0.001) and in-hospital mortality (OR, 2.88; 95% CI, 1.05-7.88; p = 0.039) in multivariable analysis. Each 100-mg increase in the day-of-OHT amiodarone dose (OR, 1.55; 95% CI, 1.26-1.90) and each 18,300-mg increase in the 6-month cumulative dose (OR, 1.67; 95% CI, 1.31-2.15) was associated with increased odds of developing severe PGD (p < 0.001 for both). CONCLUSIONS: Amiodarone use pre-OHT is independently associated with increased incidence of severe PGD and in-hospital mortality and linearly associated with increased incidence of severe PGD in a dose-dependent manner.

来源:J Heart Lung Transplant,查看原文。版权归原作者所有。

引用

  1. Wright M, Takeda K, Mauro C, et al. Dose-dependent association between amiodarone and severe primary graft dysfunction in orthotopic heart transplantation. J Heart Lung Transplant. 2017. PMID: 28583372. doi:10.1016/j.healun.2017.05.025

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。